Cancer Research Institute (CRI) Seed Fund

The Cancer Research Institute Seed Fund is the venture-investment vehicle of CRI, a long-standing nonprofit focused on cancer immunotherapy. Headquartered in New York, the fund channels philanthropic capital into very early-stage commercialization of cancer immunotherapy science, sitting at the intersection of academic research and company formation. Its mandate covers biotech and pharma therapeutics, with an explicit bias toward immunotherapy approaches rather than oncology broadly. Limited public information is available on a named partner team or detailed portfolio composition in a typical venture-style format, given the fund operates inside a research institute structure rather than as a standalone investment firm.

The fund participates at Pre-Seed and Seed stages with checks in the $250k to $1M range, sizing that fits the moment between an academic project and a fundable Series A. That positioning is deliberate: the fund is built to bridge the translational gap that often kills promising immunotherapy programs before they can attract conventional biotech investors. The geographic focus follows the science, with strong natural alignment to US academic medical centers and the immunotherapy research community CRI has cultivated for decades.

For founders and translational investigators, the relationship is part funding, part scientific credibility. Engagement should center on the immunology rationale, the path to a credible preclinical or early clinical readout, and how the program advances cancer immunotherapy as a field. The fund is most useful for teams whose science is rigorous but commercially nascent, and whose progress would benefit from association with one of the most established immunotherapy-focused organizations in the country. Founders pursuing non-immunotherapy oncology approaches should look elsewhere.